Abstract:

From March 2014 to March 2019, 339 strains were identified as nontuberculous mycobacterium (NTM) by Roche culture and DNA microarray technology in Tianjin Haihe Hospital. Drug sensitivity test (DST) were performed. Among 339 NTM clinical isolates, the top three were M.intracellulare (38.6%, 131/339), M.cheloni-abscessus (21.2%, 72/339) and M.kansas (18.3%, 62/339). In vitro DST showed that the drug resistance rates of M.intracellular, M.Kansas an M.cheloni-abscessus to 8 antituberculosis drugs (isoniazid, rifampin, streptomycin, ethambutol, p-aminosalicylic acid, kanamycin, capreomycin, ofloxacin) were: 95.6% (108/113), 82.3% (93/113), 94.7% (107/113), 54.0% (61/113), 92.0% (69/75), 81.3% (61/75), 85.3% (64/75), 87.5% (49/56) for M.intracellulare; 100.0% (54/54),3.7% (2/54),98.1% (53/54),11.1% (6/54),95.0% (38/40),90.0% (36/40),27.5% (11/40),13.8% (4/29) for M.kansas; 96.9% (62/64),93.8% (60/64),95.3% (61/64),92.2% (59/64),88.4% (38/43),86.0% (37/43), 88.4% (38/43), 87.1% (27/31) for M.cheloni-abscessus. The clinical isolates of NTM were mainly M.intracellulare, M.cheloni-abscess and M.Kansas, of which M.intracellulare and M.cheloni-abscess had high resistance to common first-line and second-line anti tuberculosis drugs, while M.Kansas had low resistance to rifampin, ethambutol, ofloxacin and capreomycin.

Key words: Mycobacterium, atypical, Biological assay, Bacterial typing techniques, Microbial sensitivity tests, Data interpretation, statistical